Who May Be at Risk for Ozempic-Related Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Risk

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or bloating, you might be concerned about gastroparesis. The medical community has long studied how certain medications affect digestion, and recent research has focused on the link between GLP-1 receptor agonists like Ozempic and delayed gastric emptying. This page provides an objective overview of the current understanding of risk factors and what the science says.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal exits the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. The latter effect is central to its therapeutic action but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Risk Context

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. In susceptible individuals, this pharmacodynamic effect may transition from a transient, dose-dependent slowing to a chronic condition resembling idiopathic gastroparesis. The clinical presentation of Ozempic-associated gastroparesis mirrors that of other forms, with persistent nausea, vomiting, and abdominal discomfort that may persist even after drug discontinuation. Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a central concern. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of the potential for this serious complication. This gap in risk communication could be relevant in legal claims alleging failure to warn.

Statute of Limitations for Ozempic Gastroparesis Claims in Ohio

Settlement-related considerations for affected patients in Ohio hinge on the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient becomes aware of the link between the drug and the condition. This awareness may arise from a diagnosis by a healthcare provider, media reports, or legal notices. Patients should document the date of first symptoms, the date of diagnosis, and any communications with healthcare providers about the potential cause. The timeline between exposure to Ozempic and documented harm is critical: gastroparesis may develop weeks to months after starting the drug, and symptoms may persist or worsen over time. Delayed recognition of the condition can complicate the statute of limitations analysis, as the injury may not be immediately apparent. In summary, patients in Ohio who have developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery. The adequacy of warnings, the pharmacological mechanisms, and the clinical presentation all support the plausibility of a causal link. Legal consultation is recommended to assess individual circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient becomes aware of the link between the drug and the condition.

What evidence supports a link between Ozempic and gastroparesis?

Clinical trials show that gastrointestinal adverse reactions, including nausea, vomiting, and diarrhea, occur more frequently with Ozempic than placebo. Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying, which can lead to gastroparesis in susceptible individuals. The prescribing information does not specifically warn about gastroparesis, which may be relevant in failure-to-warn claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.